去甲氧柔红霉素与柔红霉素在初治急性髓系白血病诱导治疗中的疗效与安全性分析

目的:比较分析去甲氧柔红霉素联合阿糖胞苷(IA)方案与柔红霉素联合阿糖胞苷(DA)方案在初治成人急性髓系白血病(AML)(非M3)诱导治疗中的疗效及安全性。方法:选取30例AML患者,随机将患者分为研究组(IA)14例,采用去甲氧柔红霉素联合阿糖胞苷(Ara-C)方案;对照组(DA)16例采用柔红霉素联合Ara-C方案。诱导化疗1个疗程骨髓抑制期结束后,观察2组患者的完全缓解率、总有效率以及骨髓抑制阶段的不良反应率。结果:IA组的完全缓解率为71.43%,总有效率为92.88%;DA组的完全缓解率为43.75%,总有效率为68.75%;2组有效率之间比较差异有统计学意义(P0.05)。2组之间不良反应率比较,除IA组因骨髓抑制导致死亡1例外,其余差异无统计学意义(P0.05)。结论:IA方案在初治成人AML(非M3)诱导化疗中比DA方案疗效更好,除死亡1例外,不良反应无明显差异。

Efficacy and safety of the treatment of Methoxy-DNR and DNR in the induction of primary acute myeloid leukemia

Objective: To compare the efficacy of daunorubicin combined with cytarabine (Ara) and daunorubicin combined with cytosine arabinoside (DA) in the treatment of adult acute myeloid leukemia (AML) M3) in the induction of treatment efficacy and safety. METHODS: Thirty patients with AML who were admitted to our hospital from January 2011 to December 2016 were randomly divided into IA group (n = 14) and DA (n = 16). After induction of chemotherapy, the complete remission rate, total effective rate and adverse reaction rate were observed. Results: Complete remission rate was 71.43% and total effective rate was 92.88% in group IA, 43.75% and 68.75% respectively. The difference between the two groups was significant (P <0.05). There was no significant difference between the two groups in the adverse reaction rate (P> 0.05). Conclusion: IA regimen is better than DA regimen in the treatment of AML (non - M3) induction chemotherapy, and the adverse reaction rate is not significantly different.